Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

被引:1
|
作者
Kewan, Tariq [1 ,2 ]
Bewersdorf, Jan Philipp [3 ]
Blaha, Ondrej [4 ]
Stahl, Maximilian [5 ]
Al Ali, Najla H. [6 ]
DeZern, Amy E. [7 ]
Sekeres, Mikkael A. [8 ]
Carraway, Hetty E. [9 ]
Desai, Pinkal [10 ]
Griffiths, Elizabeth A. [11 ]
Stein, Eytan M. [12 ]
Brunner, Andrew M. [13 ]
Amaya, Maria L. [14 ]
Zeidner, Joshua F. [15 ]
Savona, Michael R. [16 ]
Stempel, Jessica M. [17 ]
Chandhok, Namrata Sonia [18 ]
Cochran, Hunter [19 ]
Ramaswamy, Rahul [19 ]
Singh, Abhay [20 ]
Roboz, Gail J. [21 ,22 ]
Rolles, Benjamin [23 ]
Wang, Eunice S. [24 ]
Harris, Amyah C. [25 ]
Shallis, Rory M. [1 ,2 ]
Xie, Zhuoer [26 ]
Padron, Eric [5 ,6 ]
Maciejewski, Jaroslaw P. [27 ]
Della Porta, Matteo Giovanni [28 ]
Komrokji, Rami S. [5 ,6 ]
Sallman, David A. [29 ]
Zeidan, Amer M. [17 ]
机构
[1] Yale Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[5] Dana Farber Inst, Boston, MA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[7] Johns Hopkins Univ, Sidney Kimmel CCC, Baltimore, MD USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Cleveland Clin, Leukemia Program, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA
[10] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[11] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA
[12] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA
[13] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA
[14] Univ Colorado, Div Hematol, Aurora, CO USA
[15] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[16] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[17] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol,Yale Canc Ctr, New Haven, CT USA
[18] Univ Miami, Miami, FL USA
[19] Washington Univ, St Louis, MO USA
[20] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA
[21] Weill Cornell Med, New York, NY USA
[22] New York Presbyterian Hosp, New York, NY USA
[23] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA USA
[24] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[25] Dana Farber Canc Inst, Boston, MA USA
[26] H Lee Moffitt Canc Inst, Tampa, FL USA
[27] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA
[28] IRCCS, Humanitas Clin & Res Ctr, Rozzano, Italy
[29] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
关键词
D O I
10.1182/blood-2023-186875
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:8
相关论文
共 23 条
  • [1] Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
    Takahashi, Koichi
    Patel, Keyur
    Bueso-Ramos, Carlos
    Zhang, Jianhua
    Gumbs, Curtis
    Jabbour, Elias
    Kadia, Tapan
    Andreff, Michael
    Konopleva, Marina
    DiNardo, Courtney
    Daver, Naval
    Cortes, Jorge
    Estrov, Zeev
    Futreal, Andrew
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    ONCOTARGET, 2016, 7 (12) : 14172 - 14187
  • [2] Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database
    Bewersdof, Jan Philippe
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Logothetis, Constantine
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [3] Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
    Elsa Bernard
    Yasuhito Nannya
    Robert P. Hasserjian
    Sean M. Devlin
    Heinz Tuechler
    Juan S. Medina-Martinez
    Tetsuichi Yoshizato
    Yusuke Shiozawa
    Ryunosuke Saiki
    Luca Malcovati
    Max F. Levine
    Juan E. Arango
    Yangyu Zhou
    Francesc Solé
    Catherine A. Cargo
    Detlef Haase
    Maria Creignou
    Ulrich Germing
    Yanming Zhang
    Gunes Gundem
    Araxe Sarian
    Arjan A. van de Loosdrecht
    Martin Jädersten
    Magnus Tobiasson
    Olivier Kosmider
    Matilde Y. Follo
    Felicitas Thol
    Ronald F. Pinheiro
    Valeria Santini
    Ioannis Kotsianidis
    Jacqueline Boultwood
    Fabio P. S. Santos
    Julie Schanz
    Senji Kasahara
    Takayuki Ishikawa
    Hisashi Tsurumi
    Akifumi Takaori-Kondo
    Toru Kiguchi
    Chantana Polprasert
    John M. Bennett
    Virginia M. Klimek
    Michael R. Savona
    Monika Belickova
    Christina Ganster
    Laura Palomo
    Guillermo Sanz
    Lionel Ades
    Matteo Giovanni Della Porta
    Harold K. Elias
    Alexandra G. Smith
    Nature Medicine, 2020, 26 : 1549 - 1556
  • [4] Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Qiao, Wei
    Strati, Paolo
    Khan, Navira F.
    Cortes, Jorge E.
    Hoehn, Daniela
    Hu, Jianhua
    Obrien, Susan
    Bryan, Jeffrey
    Prescott, Hillary
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [5] Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
    Bewersdorf, Philipp
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Ramaswamy, Rahul
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Gurnari, Carmelo
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [6] TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS
    Cedena, M. T.
    Rapado, I.
    Ayala, R. M.
    Onecha, E.
    Abaigar, M.
    Such, E.
    Ramos, F.
    Cervera, J. V.
    Hernandez-Rivas, J. M.
    Sanz, G.
    Martinez-Lopez, J.
    HAEMATOLOGICA, 2016, 101 : 68 - 68
  • [7] Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
    Kewan, Tariq
    Bewersdorf, Jan Philipp
    Blaha, Ondrej
    Stahl, Maximilian
    Ali, Najla Hal
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    Amaya, Maria L.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Logothetis, Constantine
    Ramaswamy, Rahul
    Rose, Ameera
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Shallis, Rory M.
    Xie, Zhuoer
    Padron, Eric
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [8] Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium
    Jabbour, Elias
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Gail, Roboz J.
    Daver, Naval G.
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney D.
    Wang, Xuemei
    Nogueras-Gonzalez, Graciela
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [9] Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network
    Rossi, Marianna
    Croci, Giorgio
    Boveri, Emanuela
    Gianelli, Umberto
    Ponzoni, Maurilio
    Giordano, Laura
    Ubezio, Marta
    Travaglino, Erica
    Morabito, Lucio
    Milanesi, Chiara
    Saba, Elena
    Borin, Lorenza
    Bernardi, Massimo
    Santini, Valeria
    Voso, Maria Teresa
    Fenu, Susanna
    Orazi, Attilio
    Santoro, Armando
    Bacigalupo, Andrea
    Rambaldi, Alessandro
    Della Porta, Matteo Giovanni
    BLOOD, 2017, 130
  • [10] Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
    Elsa Bernard
    Yasuhito Nannya
    Robert P. Hasserjian
    Sean M. Devlin
    Heinz Tuechler
    Juan S. Medina-Martinez
    Tetsuichi Yoshizato
    Yusuke Shiozawa
    Ryunosuke Saiki
    Luca Malcovati
    Max F. Levine
    Juan E. Arango
    Yangyu Zhou
    Francesc Solé
    Catherine A. Cargo
    Detlef Haase
    Maria Creignou
    Ulrich Germing
    Yanming Zhang
    Gunes Gundem
    Araxe Sarian
    Arjan A. van de Loosdrecht
    Martin Jädersten
    Magnus Tobiasson
    Olivier Kosmider
    Matilde Y. Follo
    Felicitas Thol
    Ronald F. Pinheiro
    Valeria Santini
    Ioannis Kotsianidis
    Jacqueline Boultwood
    Fabio P. S. Santos
    Julie Schanz
    Senji Kasahara
    Takayuki Ishikawa
    Hisashi Tsurumi
    Akifumi Takaori-Kondo
    Toru Kiguchi
    Chantana Polprasert
    John M. Bennett
    Virginia M. Klimek
    Michael R. Savona
    Monika Belickova
    Christina Ganster
    Laura Palomo
    Guillermo Sanz
    Lionel Ades
    Matteo Giovanni Della Porta
    Alexandra G. Smith
    Yesenia Werner
    Nature Medicine, 2021, 27 : 562 - 562